Swiss pharma giant Novartis to close biotech firm Morphosys
Novartis acquired Morphosys earlier this year for a total of €2.7 billion (CHF2.5 billion).
Keystone-SDA
Select your language
Generated with artificial intelligence.
Listening: Swiss pharma giant Novartis to close biotech firm Morphosys
Novartis is closing the German biotech company Morphosys, acquired earlier this year, according to German press reports confirmed by the Basel-based pharmaceutical giant. Hundreds of jobs are affected.
Novartis decided in November 2024 to close the Morphosys sites in Germany and the United States by the end of 2025 and integrate all portfolio activities into the company, according to an article in the German magazine WirtschaftsWoche on Thursday. Around 330 jobs could be lost. Contacted by the AWP news agency, the Basel-based pharmaceutical giant confirmed this information.
Novartis acquired Morphosys earlier this year for a total of €2.7 billion (CHF2.5 billion). With this acquisition, the Basel-based company was hoping to gain access to Pelabresib, a treatment in development for myelofibrosis, a potentially fatal chronic bone marrow disease.
But concerns have recently arisen about the efficacy and safety of this promising drug, according to the German magazine. A few weeks ago, Novartis re-assessed Morphosys and corrected its value by $800 million.
“All merger-and-acquisition activities in research and development involve a certain degree of risk and depend on circumstances. Novartis regularly reviews its portfolio and organizational structure in order to be better positioned for the future and to meet patients’ needs,” the Basel-based pharmaceutical giant explained to WirtschaftsWoche.
Morphosys was founded in 1992 and is one of Germany’s oldest biotech companies. Until recently, the company’s shares were listed in Frankfurt and New York.
Translated from French with DeepL/gw
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.
If you want to know more about how we work, have a look here, if you want to learn more about how we use technology, click here, and if you have feedback on this news story please write to english@swissinfo.ch.
What factors should be taken into account when inheriting Swiss citizenship abroad?
Should there be a limit to the passing on of Swiss citizenship? Or is the current practice too strict and it should still be possible to register after the age of 25?
US storm continues to sweep through Swiss stock market
This content was published on
The Swiss stock market continued to trade in the red mid-afternoon on Monday, following in the wake of the world's stock markets, which fell heavily as a result of the trade war launched by Donald Trump.
This content was published on
The referendum committee announced in Bern on Monday that it had collected more than 60,000 signatures against the e-ID project. The initials still need to be approved.
This content was published on
The number of offences committed by minors in canton Ticino, southern Switzerland, rose by over 20% in 2024 compared to the previous year.
Swiss trout and pike found with excessive PFAS levels
This content was published on
Trout and pike in the lakes of western Switzerland contain excessive levels of the chemical group PFAS. This could jeopardise their saleability.
Swiss unions call for shorter days for construction workers
This content was published on
Construction workers need shorter days, say Swiss trade unions. Demonstrations are planned in Zurich and Lausanne on May 17.
Rapeseed restrictions cause problems for Swiss farmers
This content was published on
More and more Swiss farmers are abandoning rapeseed cultivation because they lack the means to protect the sensitive plants from pests.
Tariffs: Swiss index SMI down sharply in pre-market trading
This content was published on
The trade war unleashed by US President Donald Trump is causing a sell-off. According to experts' calculations, the leading Swiss SMI index is likely to fall by around 2%.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.